LEVINDAL HEBREW GER. CTR. & HOSPT. — History
CCN 210064 | 3-year financial timeline | COVID resilience: 77/100
🛡️ Public data only — no PHI permitted on this instance.
$88M
Latest Revenue (FY2022)
+7.5%
Revenue CAGR (3yr)
5.9%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $76M | $95M | $88M | -7.3% | +7.5% |
| Operating Expenses | $82M | $92M | $83M | -10.0% | +0.4% |
| Operating Margin | -7.9% | 3.1% | 5.9% | +92.1% | +0.0% |
| Net Income | $-6M | $3M | $5M | +78.2% | +0.0% |
| Licensed Beds | 120 | 120 | 120 | +0.0% | +0.0% |
| Total Patient Days | 28,063 | 31,295 | 30,335 | -3.1% | +4.0% |
| Medicare Day % | 78% | 73% | 72% | -1.2% | -4.1% |
| Medicaid Day % | 2% | 3% | 3% | +18.1% | +19.0% |
COVID Impact & Recovery
Resilience Score: 77/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +15.6% ($76M → $88M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+7.5%
This Hospital
+7.6%
State Avg
Latest Margin
5.9%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $94M | 12.7% |
| FY2024 (proj) | $100M | 19.6% |
| FY2025 (proj) | $106M | 26.5% |